IGF-1 DES: The Complete Guide

IGF-1 DES = des(1-3)IGF-I = destripeptide-IGF-I. Native human IGF-I is 70 amino acids; DES is the same molecule lacking the first three N-terminal residues (Gly-Pro-Glu, the “GPE” tripeptide), giving a 67-amino-acid peptide of ~7.4 kDa.

Origin (this is the unusual fact):

• Naturally occurring — not synthetic in origin like LR3.
• Bovine colostrum. Francis et al. 1988 (PMID 3390164) isolated and sequenced “a truncated form of IGF-I” from bovine colostrum; higher biological activity than intact IGF-I in chick embryo fibroblasts.
• Human fetal brain. Sara, Carlsson-Skwirut and colleagues at Karolinska independently identified the same truncation; PMID 2574573. The cleaved tripeptide GPE itself (“glypromate”) is a distinct neuroactive peptide.
• Recombinant production: McKinnon et al. 1991 (PMID 1883485) expressed des(1-3)IGF-I in CHO cells, establishing it as an industrially producible recombinant.

Why deletion of three residues matters:

The first three residues (GPE) sit at the N-terminus of the IGF-I B domain — the principal binding determinant for the IGFBP family. Removing GPE gutts IGFBP affinity while leaving IGF-1R binding largely intact (Bagley 1989, PMID 2730580). The free fraction available to the receptor therefore dominates in vivo, and the apparent potency rises.

Regulatory status:

• FDA (US): not approved. No NDA, no IND. Not on the 503A bulks list. The only FDA-approved IGF-I product is mecasermin (Increlex) — recombinant native rhIGF-I (NDA 021839) for severe primary IGF-I deficiency in pediatrics. Increlex is not DES.
• EMA (EU): no marketing authorization for DES.
• WADA 2026: prohibited at all times under S2.3 (Growth Factors and Growth Factor Modulators). The S2.3 list covers “IGF-1 (mecasermin) and its analogues” — DES is an analogue. Detection in human plasma is validated via LC-HRMS (Thomas 2017, PMID 28668757; Mongongu 2021, PMID 33587816).

DES is a full IGF-1R agonist. Engagement is qualitatively identical to native IGF-I at the type-1 IGF receptor. The biological difference is kinetic, not pharmacodynamic.

Receptor pathway:

1. DES binds IGF-1R extracellular α-subunits → tyrosine autophosphorylation of intracellular β-subunit kinase domains.
2. Recruitment of IRS-1/2 adaptor proteins → bifurcates into the canonical IGF-1R cascades:
   • PI3K → AKT → mTORC1 (the “anabolic” axis): protein synthesis, ribosomal biogenesis, satellite-cell proliferation, GLUT4-mediated glucose uptake, AKT-mediated cell survival via FOXO/BAD phosphorylation.
   • RAS → RAF → MEK → ERK1/2 (MAPK): mitogenesis, proliferation, differentiation.
3. Insulin receptor cross-binding at low affinity — same as native IGF-I, but the higher free fraction means per-microgram hypoglycemic effect is greater for DES (PMID 9415072, Tomas 1997, pigs and marmosets).

The "site-localized" framing — what mechanism actually says:

DES does not have a tissue-targeting motif. Like all IGF-I analogues it diffuses freely from injection site into circulation. The reason DES is treated as “local” in community practice is purely pharmacokinetic: with a circulating t½ on the order of minutes, the drug doesn’t reach systemic steady-state distribution before clearance. A high concentration persists at and around the injection depot for the few minutes of receptor occupancy that drive downstream signaling.

The honest framing: “transient peri-injection dominance before systemic dilution and clearance” — not molecular tissue targeting.

No GH/IGF-I feedback suppression:

Because DES is cleared quickly, a typical SC injection does not produce sustained hypothalamic-pituitary suppression of endogenous GH or IGF-I. This is the key mechanistic difference vs LR3 for stack design: DES is in principle compatible with GHRH analogs / GHRPs (CJC-1295, ipamorelin, sermorelin) where LR3 is mechanistically discouraged.

LR3 and DES are both IGFBP-resistant IGF-1R agonists. They are not two flavors of the same thing. They differ on the dimension that matters most for use-case design: half-life and distribution.

Feature	IGF-1 DES (des(1-3)IGF-I)	IGF-1 LR3
Sequence change vs native IGF-I	Deletion of N-terminal Gly-Pro-Glu; 67 aa	Substitution Glu³→Arg³ + 13-aa N-terminal extension; 83 aa
Origin	Naturally occurring (bovine colostrum, fetal brain)	Engineered (CSIRO, ~1989–1992)
MW	~7.4 kDa	~9.2 kDa
IGFBP affinity	Very low (deletion removes IGFBP-binding handle)	Very low (Arg³ + N-terminal extension disrupts contact surface)
Plasma half-life (load-bearing)	Short — minutes-scale	Longer — commonly cited 20–30 hours
Distribution	Peri-injection-dominant before clearance	Systemic — reaches steady-state distribution
Endogenous GH/IGF-I suppression	Minimal at typical doses	Significant (PMIDs 7561636 guinea pig; 9488001 pig)
Stack with GH secretagogues	Plausible — DES too short-acting to drive somatostatin tone	Mechanistically discouraged — LR3 short-circuits the secretagogue response
Community use case	“Localized hypertrophy / site enhancement,” post-workout into target muscle	“Systemic anabolic,” daily SC, whole-body

One sentence to memorize: DES and LR3 are both IGFBP-resistant IGF-1R agonists; DES is short-acting and used because clearance is fast enough to keep most of the dose near the injection site, while LR3 is long-acting and used because the dose reaches and stays at every IGF-1R-expressing tissue in the body.

No human RCT of DES for hypertrophy or anti-aging exists. The published evidence base is biochemistry, animal pharmacology (rat anabolism, pig/marmoset hypoglycemia), and anti-doping detection.

Tier-2 anchors (rat anabolism / catabolic-state rescue):

• PMID 2962574 (Ballard 1987 BBRC, founding paper): DES is more biologically active than intact IGF-I in cell-based assays.
• PMID 1999680 (Tomas 1991 J Endocrinol): nitrogen balance + muscle protein metabolism in nitrogen-restricted rats.
• PMID 1996625 (Lemmey 1991 Am J Physiol): DES enhances growth in rats after gut resection.
• PMID 1928375 (Martin 1991 Am J Physiol): DES enhances growth in rats with reduced renal mass.
• PMID 1371669 (Tomas 1992 Biochem J): DES is anabolic in dexamethasone-treated rats (catabolism rescue).
• PMID 7683875 (Tomas 1993 Biochem J): DES restores growth in diabetic rats without all the insulin-like effects.
• PMID 9415072 (Tomas 1997 J Endocrinol): DES shows more potent and prolonged hypoglycemic action than native IGF-I in pigs and marmosets — the cleanest in-vivo “more potent per microgram” anchor.

The "10x more potent in vitro" framing — honest version:

Traces to the Ballard 1987 paper (PMID 2962574) and Carlsson-Skwirut 1989 (PMID 2469478). DES is approximately an order of magnitude more active per nanomolar in cell-based protein-synthesis assays where IGFBP binding sequesters intact IGF-I. That ratio applies to IGFBP-rich in-vitro assays specifically; the in-vivo ratio is closer to 2–3× per microgram (the rat/pig/marmoset literature). Stating “10× more potent” without the assay context overstates the case.

Anti-doping detection (proves DES IS detectable):

• PMID 28668757 (Thomas 2017 Growth Horm IGF Res): LC-MS detection of LongR3-IGF-I, R3-IGF-I, and Des1-3 IGF-I in human plasma.
• PMID 33587816 (Mongongu 2021 Drug Test Anal): immunopurification + high-resolution MS for anti-doping.

If you compete in a WADA-tested sport, DES is detectable. Don’t use it.

No human RCT establishes a DES dose for hypertrophy. The protocol below is community / vendor convention.

Parameter	Common Range
Dose per injection	20–100 µg
Frequency	1–2× daily on training days
Timing	Immediately pre- or post-workout, into or near the trained muscle
Cycle length	4–6 weeks on / 4–6 weeks off
Route	SC or IM (intramuscular near the target muscle is the community convention for the “site enhancement” effect)

The community pattern is to inject immediately around or post-workout, into or near the trained muscle, for whatever localized action the depot kinetics permit. The mechanistic premise (transient peri-injection dominance) is plausible. The human evidence base for site-specific muscle-fiber gain with DES is community reports only — no imaging, biopsy, or histology study has been published.

DES reconstitution diverges from LR3 at the solvent question.

Bacteriostatic water (typical):

• Most vendors describe DES as tolerant of bacteriostatic water at neutral pH.
• For a 1 mg vial in 1 mL BAC: 1 mg/mL (1000 µg/mL) → 1 unit on a U-100 = 10 µg; a 50 µg dose = 5 units.

0.6% acetic acid (some vendors recommend as a conservative default):

• Maintains solubility under storage conditions where some peptide chemistries can lose activity in neutral solution.
• If your vendor explicitly recommends acetic acid, use it.

Storage:

• Lyophilized: stable at room temperature short-term; refrigerate for longer.
• Reconstituted: refrigerate. Use within 14–21 days.
• For long storage: freeze single-use aliquots.

For the full reconstitution protocol, see the Bacteriostatic Water guide.

Hypoglycemia — the dominant acute risk:

• IGF-I cross-activates the insulin receptor at low affinity. For DES, the per-microgram hypoglycemic effect is greater than for native IGF-I (PMID 9415072, pigs and marmosets) because the higher free fraction puts more peptide on the receptor.
• Onset typically 30–90 min post-injection; can be delayed several hours.
• Symptoms: tremor, sweating, tachycardia, hunger, confusion, visual changes; severe → syncope, seizure, loss of consciousness.
• Mitigations: dose with a carbohydrate-containing meal within 20 min (the FDA Increlex label requirement; defensible as a class precaution); have fast-acting glucose available; do not dose pre-bed; do not stack with insulin or insulin secretagogues.

Cancer-axis class concern:

• IGF-1R signaling is mitogenic and anti-apoptotic. Observational and Mendelian-randomization evidence supports a probable causal association between higher circulating IGF-I and incident colorectal cancer (PMID 32717139), with positive observational signals for prostate cancer (PMID 26921328) and postmenopausal ER-positive breast cancer.
• Effect sizes per SD in the population are modest (HR ~1.07–1.30), but DES use produces a stimulus outside the physiological range.
• Active or prior cancer is a contraindication.

Other class concerns:

• Localized tissue overgrowth / asymmetric hypertrophy. The intent of “site enhancement” is localized growth; the failure mode is when growth becomes disproportionate, distorts function, or affects the wrong tissue (subcutaneous fat fibrosis, fascial thickening, muscle-belly asymmetry).
• Cardiac / visceral hypertrophy with sustained dosing — class concern from rodent IGF-I studies (PMIDs 8023938, 7561636).
• Insulin resistance with chronic use — class effect, documented for rhGH and tesamorelin.
• Soft-tissue / cartilage / acromegaly-like changes — mechanistically plausible by analogy (PMID 15523595, IGF-I mandibular enlargement in rats); not characterized in human DES data.
• Edema / sodium retention — IGF-I-axis class effect; less commonly reported with DES than with LR3 because total systemic exposure per dose is lower.

No published human safety data for DES specifically. Everything above is mechanism-anchored, animal-anchored, or extrapolated from the Increlex label.

• Active or prior cancer — absolute contraindication. The conservative position for any IGF-1R agonist.
• Pre-cancerous conditions (e.g., known dysplasia, intraductal papillary neoplasms).
• Uncontrolled diabetes — hypoglycemia risk in combination with insulin / sulfonylureas.
• Active proliferative diabetic retinopathy — class concern from Increlex label.
• Pregnancy / lactation — no safety data.
• Pediatric use without specialist supervision — growth plate / IGF-I axis interactions are specialist territory.
• Recent stroke / cardiac events — class caution for any anabolic stimulus.
• Concurrent insulin or insulin secretagogues — additive hypoglycemia.
• Athletes subject to anti-doping testing — do not use. WADA S2.3; detectable via LC-HRMS.

• IGF-1 LR3 — same IGFBP escape strategy, opposite PK design. See the LR3-vs-DES table above.
• MGF (mechano growth factor / IGF-1Ec) — both are IGF-I family members; the resemblance ends there. MGF is a splice variant of the IGF-I gene; the active species is hypothesized to be the cleaved 24-aa E-peptide acting via a non-IGF-1R mechanism. DES is a canonical IGF-1R agonist.
• IGF-2. Separate gene product (~67 aa, similar size but unrelated sequence beyond the IGF-family fold). Binds IGF-2R preferentially. Not in clinical or community use as an injectable.
• Insulin. Both can engage the insulin receptor and lower blood glucose. Insulin is far more potent at IR (DES binds at ~1/100th of insulin’s affinity). The clinical hazard is interactive: do not stack DES with insulin or insulin secretagogues.
• Mecasermin (Increlex) — recombinant native rhIGF-I, FDA-approved for severe primary IGF-I deficiency in pediatrics. DES is not Increlex. The truncated form is not an FDA-approved product.